164 related articles for article (PubMed ID: 23131254)
1. CYP2E1 RsaI/PstI polymorphism and risk of anti-tuberculosis drug-induced liver injury: a meta-analysis.
Deng R; Yang T; Wang Y; Tang N
Int J Tuberc Lung Dis; 2012 Dec; 16(12):1574-81. PubMed ID: 23131254
[TBL] [Abstract][Full Text] [Related]
2. Association of genetic polymorphisms of
Yang S; Hwang SJ; Park JY; Chung EK; Lee JI
BMJ Open; 2019 Aug; 9(8):e027940. PubMed ID: 31375612
[TBL] [Abstract][Full Text] [Related]
3. Update meta-analysis of the CYP2E1 RsaI/PstI and DraI polymorphisms and risk of antituberculosis drug-induced hepatotoxicity: evidence from 26 studies.
Wang FJ; Wang Y; Niu T; Lu WX; Sandford AJ; He JQ
J Clin Pharm Ther; 2016 Jun; 41(3):334-40. PubMed ID: 27062377
[TBL] [Abstract][Full Text] [Related]
4. Updated meta-analysis of the association between CYP2E1 RsaI/PstI polymorphisms and lung cancer risk in Chinese population.
Wang YD; Yang HY; Liu J; Wang HY
Asian Pac J Cancer Prev; 2014; 15(13):5411-6. PubMed ID: 25040958
[TBL] [Abstract][Full Text] [Related]
5. The association between CYP2E1 polymorphisms and hepatotoxicity due to anti-tuberculosis drugs: a meta-analysis.
Sheng YJ; Wu G; He HY; Chen W; Zou YS; Li Q; Zhong L; Huang YM; Deng CL
Infect Genet Evol; 2014 Jun; 24():34-40. PubMed ID: 24607341
[TBL] [Abstract][Full Text] [Related]
6. CYP2E1 RsaI/PstI polymorphism and liver cancer risk among east Asians: a HuGE review and meta-analysis.
Tian Z; Li YL; Zhao L; Zhang CL
Asian Pac J Cancer Prev; 2012; 13(10):4915-21. PubMed ID: 23244081
[TBL] [Abstract][Full Text] [Related]
7. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis.
Huang YS; Chern HD; Su WJ; Wu JC; Chang SC; Chiang CH; Chang FY; Lee SD
Hepatology; 2003 Apr; 37(4):924-30. PubMed ID: 12668988
[TBL] [Abstract][Full Text] [Related]
8. Cytochrome P450 2E1 RsaI/PstI polymorphism and risk of esophageal cancer: A meta-analysis of 17 case-control studies.
Leng WD; Zeng XT; Chen YJ; Duan XL; Niu YM; Long RP; Luo ZX
Exp Ther Med; 2012 Nov; 4(5):938-948. PubMed ID: 23226753
[TBL] [Abstract][Full Text] [Related]
9. CYP2E1 PstI/RsaI polymorphism and interaction with alcohol consumption in hepatocellular carcinoma susceptibility: evidence from 1,661 cases and 2,317 controls.
Liu C; Wang H; Pan C; Shen J; Liang Y
Tumour Biol; 2012 Aug; 33(4):979-84. PubMed ID: 22249978
[TBL] [Abstract][Full Text] [Related]
10. Genetic polymorphisms of cytochrome P450 and glutathione S-transferase associated with antituberculosis drug-induced hepatotoxicity in Chinese tuberculosis patients.
Wang T; Yu HT; Wang W; Pan YY; He LX; Wang ZY
J Int Med Res; 2010; 38(3):977-86. PubMed ID: 20819434
[TBL] [Abstract][Full Text] [Related]
11. NAT2 and CYP2E1 polymorphisms associated with antituberculosis drug-induced hepatotoxicity in Chinese patients.
An HR; Wu XQ; Wang ZY; Zhang JX; Liang Y
Clin Exp Pharmacol Physiol; 2012 Jun; 39(6):535-43. PubMed ID: 22506592
[TBL] [Abstract][Full Text] [Related]
12. CYP2E1, GSTM1 and GSTT1 genetic polymorphisms and susceptibility to antituberculosis drug-induced hepatotoxicity: a nested case-control study.
Tang SW; Lv XZ; Zhang Y; Wu SS; Yang ZR; Xia YY; Tu DH; Deng PY; Ma Y; Chen DF; Zhan SY
J Clin Pharm Ther; 2012 Oct; 37(5):588-93. PubMed ID: 22335459
[TBL] [Abstract][Full Text] [Related]
13. The association between cytochrome P450 polymorphisms and anti-tuberculosis drug-induced liver injury: a systematic review and meta-analysis.
Liu X; Ren S; Zhang J; Xu D; Jiang F; Jiang P; Feng J; Deng F
Ann Palliat Med; 2021 Jun; 10(6):6518-6534. PubMed ID: 34154362
[TBL] [Abstract][Full Text] [Related]
14. [Association of P450-2E1 and GSTM1 genetic polymorphisms with susceptibility to antituberculosis drug-induced hepatotoxicity].
Wang T; Wang W; Wang ZY; Pan YY; Su QQ; He LX
Zhonghua Jie He He Hu Xi Za Zhi; 2009 Aug; 32(8):585-7. PubMed ID: 19958676
[TBL] [Abstract][Full Text] [Related]
15. N-acetyl transferase 2 and cytochrome P450 2E1 genes and isoniazid-induced hepatotoxicity in Brazilian patients.
Santos NP; Callegari-Jacques SM; Ribeiro Dos Santos AK; Silva CA; Vallinoto AC; Fernandes DC; de Carvalho DC; Santos SE; Hutz MH
Int J Tuberc Lung Dis; 2013 Apr; 17(4):499-504. PubMed ID: 23394127
[TBL] [Abstract][Full Text] [Related]
16. Functional RsaI/PstI polymorphism in cytochrome P450 2E1 contributes to bladder cancer susceptibility: evidence from a meta-analysis.
Deng XD; Gao Q; Zhang B; Zhang LX; Zhang W; Mu Er ZE; Xie Y; Ma Y; Liu Y
Asian Pac J Cancer Prev; 2014; 15(12):4977-82. PubMed ID: 24998574
[TBL] [Abstract][Full Text] [Related]
17. NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis.
Lee SW; Chung LS; Huang HH; Chuang TY; Liou YH; Wu LS
Int J Tuberc Lung Dis; 2010 May; 14(5):622-6. PubMed ID: 20392357
[TBL] [Abstract][Full Text] [Related]
18. Drug-metabolising enzyme polymorphisms and predisposition to anti-tuberculosis drug-induced liver injury: a meta-analysis.
Sun F; Chen Y; Xiang Y; Zhan S
Int J Tuberc Lung Dis; 2008 Sep; 12(9):994-1002. PubMed ID: 18713495
[TBL] [Abstract][Full Text] [Related]
19. Functional PstI/RsaI polymorphism in CYP2E1 is associated with the development, progression and poor outcome of gastric cancer.
Feng J; Pan X; Yu J; Chen Z; Xu H; El-Rifai W; Zhang G; Xu Z
PLoS One; 2012; 7(9):e44478. PubMed ID: 22957075
[TBL] [Abstract][Full Text] [Related]
20. Does CYP2E1 RsaI/PstI polymorphism confer head and neck carcinoma susceptibility?: A meta-analysis based on 43 studies.
Zhuo X; Song J; Liao J; Zhou W; Ye H; Li Q; Xiang Z; Zhang X
Medicine (Baltimore); 2016 Oct; 95(43):e5156. PubMed ID: 27787372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
